Tirzepatide Dosing: FDA-Label Range, Titration, and Format

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide is part of the PlexusDx Education Hub — plain-language explainers on GLP-1 biology, weight-management protocols, and the genetic factors that sit underneath every metabolic decision.

Questions about the "tirzepatide vial" are usually questions about dosing: what doses exist, how the medication is given, and why the numbers climb in steps. Those facts are documented in the FDA label, and this guide reports them factually. What it does not do is tell you which schedule to follow — that is a clinical decision for a provider who knows your history.

The FDA-label dose range

Per the tirzepatide FDA label, dosing begins at a 2.5 mg starting dose, with maintenance doses of 5, 10, or 15 mg per week. Tirzepatide is administered as a once-weekly subcutaneous injection in its FDA-approved formulation. The label frames this as a graduated concept: begin at the lowest dose so the body can adapt to GLP-1 pathway activation, then increase under prescriber supervision according to tolerability and response.

Why the dose climbs in steps

Slow titration is the standard approach across the GLP-1 class for one main reason: gastrointestinal side effects, nausea especially, are most pronounced during dose escalation. The label's titration schedule is built to soften those symptoms while keeping the therapy moving forward. Real-world data associate skipped or accelerated titration with higher discontinuation rates, which is why the graduated path is the norm rather than the exception.

What a provider weighs on dose

Dose selection, titration speed, and later adjustments are individualized clinical decisions. Typical discussion points include baseline metabolic status, kidney function, gastrointestinal history, prior medication tolerability, and the FDA-approved indication the prescription is written for. The consistent rule across all of it: never adjust GLP-1 receptor agonist dosing on your own.

The format behind the numbers

Because tirzepatide is delivered as a once-weekly subcutaneous injection, the full administration protocol — timing, storage, and any technique guidance — lives in the FDA label and the patient information leaflet that ships with the medication. Your prescriber and pharmacist walk you through it. This article deliberately stops at reporting the dose range and format rather than offering how-to direction.

The genetic context underneath dosing

Variants in GIPR, GLP1R, and FTO sit upstream of any GLP-1 protocol, shaping baseline appetite regulation, satiety signaling, and incretin response. They do not predict how you will respond to tirzepatide or which dose fits you — but they are part of the broader metabolic picture that informs an individualized decision with a provider.

PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide protocol. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including GIPR, GLP1R, and FTO variants that shape baseline biology. It never predicts dose response; it is the test before you invest context for a provider conversation.

Why this article stops at reporting the facts

There is a deliberate line between reporting what a label says and telling someone how to use a medication, and this guide stays on the reporting side of it. Knowing that the label defines a starting dose and a set of maintenance doses is useful context for a conversation; deciding which of those applies to you, and how quickly to move between them, is a judgment only a prescriber can make with your full history in view. The same goes for what to do about a difficult titration week. Understanding the structure of the schedule helps you ask better questions, but the schedule you actually follow should always come from your provider.

Read this way, the dose numbers are context rather than a prescription. Knowing the label range and the logic of titration helps you follow — and ask about — the plan your provider sets, but the specific schedule always belongs to the clinician who knows your complete medical picture.

Frequently Asked Questions

What is the FDA-approved dosing for tirzepatide?

Per the tirzepatide FDA label, dosing begins at 2.5 mg, with maintenance doses of 5, 10, or 15 mg per week, following a graduated titration approach. Specific dose selection and titration speed are individualized clinical decisions. Always follow the schedule your prescriber sets, and never adjust GLP-1 dosing on your own.

How is tirzepatide administered?

Tirzepatide is given as a once-weekly subcutaneous injection in its FDA-approved formulation. The complete administration protocol — timing, storage, and any injection-technique guidance — appears in the FDA label and the patient information leaflet included with the medication. Your prescriber and pharmacist will walk you through the specifics.

Why does tirzepatide use a titration schedule?

Titration reduces gastrointestinal side effects such as nausea, vomiting, and diarrhea that are most pronounced during dose escalation. The graduated schedule lets the body adapt to GLP-1 pathway activation and improves tolerability. Real-world data link skipped titration to higher discontinuation rates, which is why the step-up approach is standard.

Can genetics guide my tirzepatide dose?

No. The Precision Peptide Genetic Test does not predict tirzepatide dose response or titration tolerability. It reads pathway-level variants in genes such as GIPR and GLP1R that shape baseline GLP-1 biology, offering context for the broader protocol conversation with a healthcare provider rather than serving as a dose-selection tool.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and peptide explainers.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.